Clinical trial
A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
NCT06049082 is registered in ClinicalTrials.gov with Krystal Biotech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
- Lead sponsor
- Krystal Biotech, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 15, 2024
- Completion date
- December 31, 2026
- Enrollment
- 15 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.